High Expression of the Thalidomide-Binding Protein Cereblon (CRBN) Is Associated with Improved Clinical Response in Patients with Multiple Myeloma Treated with Lenalidomide and Dexamethasone

被引：3
|
作者：
Heintel, Daniel [1 ]
Bolomsky, Arnold [1 ]
Schreder, Martin [1 ]
Pfeifer, Sabine [1 ]
Zojer, Niklas [1 ]
Jaeger, Ulrich [2 ]
Ludwig, Heinz [1 ]
机构：
[1] Wilhelminenhosp, Ctr Oncol & Hematol, Dept Internal Med 1, Vienna, Austria
[2] Med Univ Vienna, Vienna, Austria
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.2879.2879
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1242 / 1243
页数：2
相关论文
共 50 条
  • [1] High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
    Heintel, Daniel
    Rocci, Alberto
    Ludwig, Heinz
    Bolomsky, Arnold
    Caltagirone, Simona
    Schreder, Martin
    Pfeifer, Sabine
    Gisslinger, Heinz
    Zojer, Niklas
    Jaeger, Ulrich
    Palumbo, Antonio
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (05) : 695 - 700
  • [2] High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide
    Klimowicz, Alexander
    Neri, Paola
    Belch, Andrew
    Dean, Michelle
    Ren, Li
    Gratton, Kathy
    Slaby, Jiri
    Johnson, Jordan
    Duggan, Peter
    Stewart, Douglas A.
    Bahlis, Nizar J.
    BLOOD, 2012, 120 (21)
  • [3] ASSOCIATION OF BASELINE CEREBLON (CRBN) EXPRESSION WITH CLINICAL RESPONSE, PROGNOSTIC PARAMETERS, AND β-CATENIN IN PATIENTS WITH MM TREATED WITH LENALIDOMIDE AND DEXAMETHASONE
    Heintel, D.
    Rocci, A.
    Caltagirone, S.
    Bolomsky, A.
    Schreder, M.
    Zojer, N.
    Jaeger, U.
    Palumbo, A.
    Ludwig, H.
    HAEMATOLOGICA, 2012, 97 : 331 - 332
  • [4] High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance
    Broyl, Annemiek
    Kuiper, Rowan
    van Duin, Mark
    van der Holt, Bronno
    el Jarari, Laila
    Bertsch, Uta
    Zweegman, Sonja
    Buijs, Arjan
    Hose, Dirk
    Lokhorst, Henk M.
    Goldschmidt, Hartmut
    Sonneveld, Pieter
    BLOOD, 2013, 121 (04) : 624 - 627
  • [5] Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
    Phoebe A. Huang
    Shaunna L. Beedie
    Cindy H. Chau
    David J. Venzon
    Sheryl Gere
    Dickran Kazandjian
    Neha Korde
    Sham Mailankody
    Ola Landgren
    William D. Figg
    Scientific Reports, 9
  • [6] Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
    Huang, Phoebe A.
    Beedie, Shaunna L.
    Chau, Cindy H.
    Venzon, David J.
    Gere, Sheryl
    Kazandjian, Dickran
    Korde, Neha
    Mailankody, Sham
    Landgren, Ola
    Figg, William D.
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [7] Prognostic value and clinical correlations of serum cereblon (CRBN) levels in multiple myeloma patients treated with Lenalidomide/Dexa-methasone (RD)
    Gkioka, Annita Ioanna
    Repousis, Panagiotis
    Papaioannou, Paraskevi
    Tryfou, Thomais
    Rougkala, Niki
    Dimou, Maria
    Iliakis, Theodoros
    Pardalis, Vasileios
    Bitsani, Aikaterini
    Koudouna, Aspasia
    Grafakos, Ioannis
    Panayiotidis, Panayiotis
    Kyrtsonis, Mariechristine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E117 - E117
  • [8] Cereblon (CRBN) Gene Polymorphisms Predict Clinical Response and Progression-Free Survival in Multiple Myeloma Patients Treated with Lenalidomide: A Pharmacogenetic Study of Immense Consortium
    Iskierka-Jazdzewska, Elzbieta
    Stepien, Anna
    Canzian, Federico
    Martino, Alessandro
    Campa, Daniele
    Stein, Angelika
    Krawczyk-Kulis, Malgorzata
    Rybicka, Malwina
    Kyrcz-Krzemien, Slawomira
    Butrym, Aleksandra K.
    Mazur, Grzegorz
    Jurczyszyn, Artur J.
    Zawirska, Daria
    Grzasko, Norbert
    Tomczak, Waldemar
    Subocz, Edyta
    Watek, Marzena
    Pasiarski, Marcin
    Rymko, Marcin
    Calbecka, Malgorzata
    Druzd-Sitek, Agnieszka
    Walewski, Jan
    Kruszewski, Marcin
    Razny, Malgorzata
    Zaucha, Jan M.
    Dudzinski, Marek
    Gaj, Pawel
    Warzocha, Krzysztof
    Jamroziak, Krzysztof
    BLOOD, 2014, 124 (21)
  • [9] Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
    Shang-Yi Huang
    Chung-Wu Lin
    Hsiu-Hsia Lin
    Ming Yao
    Jih-Luh Tang
    Shang-Ju Wu
    Yao-Chang Chen
    Hsiao-Yun Lu
    Hsin-An Hou
    Chien-Yuan Chen
    Wen-Chien Chou
    Woei Tsay
    Sheng-Je Chou
    Hwei-Fang Tien
    Annals of Hematology, 2014, 93 : 1371 - 1380
  • [10] Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
    Huang, Shang-Yi
    Lin, Chung-Wu
    Lin, Hsiu-Hsia
    Yao, Ming
    Tang, Jih-Luh
    Wu, Shang-Ju
    Chen, Yao-Chang
    Lu, Hsiao-Yun
    Hou, Hsin-An
    Chen, Chien-Yuan
    Chou, Wen-Chien
    Tsay, Woei
    Chou, Sheng-Je
    Tien, Hwei-Fang
    ANNALS OF HEMATOLOGY, 2014, 93 (08) : 1371 - 1380
12345